HTG

HHS Technology Group Partners with Amendola for Strategic PR and Marketing Services

Retrieved on: 
水曜日, 9月 21, 2022
ROI, Software, Centers for Medicare & Medicaid Services, Government, Center, Chronic kidney disease, COVID-19, Medicare, Twitter, The A-Team, CMS, LinkedIn, CKD, News, Partnership, Industry, Social media, HHS, HTG, Technology, Private sector, Solution, MMIS, Research, Marketing, Multimedia, Public relations, View, Pharmaceutical industry, Amendola

SCOTTSDALE, Ariz., Sept. 21, 2022 /PRNewswire/ -- Amendola, a nationally recognized, award-winning healthcare and technology public relations and marketing firm, announced that HHS Technology Group (HTG), a leader in purpose-built data and analytics software and solutions for the public and private sector, has selected the firm as its agency of record to assist with messaging, marketing, and promotion of its distinct technology solutions, including its recent collaboration on the COVID-19 Research Database designed to create a scalable, repeatable model accelerating real-world pandemic research.

Key Points: 
  • "We are excited to deepen our relationship with Amendola as we help answer some of healthcare's most complex questions.
  • Amendola is implementing a comprehensive media and communications plan for HTG to showcase the company's current technology and services, new offerings, accomplishments, customer wins, and industry partnerships.
  • HHS Technology Group is a software and solutions company serving the needs of commercial enterprises and government agencies.
  • HHS Technology Group delivers modular software solutions, custom development, and integration services for the modernization and operation of systems supporting a broad spectrum of business and government needs.

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

Retrieved on: 
火曜日, 9月 20, 2022
FPS, Therapy, Precision medicine, Centro, Molecular biology, Risk, IVO, LDT, Senior, European Molecular Biology Laboratory, Private Securities Litigation Reform Act, Information technology, Risk assessment, Bias, HTG, Industry, Patient, MPD, Cancer, Breast cancer, U.S. Securities and Exchange Commission, CIBER, Technology, Nasdaq, Diagnosis, NGS, RNA, Research, GLOBE, Overalls, SEC, Drug discovery, Recurrence, Fine chemical, Medical imaging

This innovative test for patients with HR+/HER2- early-stage breast cancer was developed by IVO and its partners to identify patients with an increased risk of developing distant metastasis or relapse who may benefit from adjuvant chemotherapy.

Key Points: 
  • This innovative test for patients with HR+/HER2- early-stage breast cancer was developed by IVO and its partners to identify patients with an increased risk of developing distant metastasis or relapse who may benefit from adjuvant chemotherapy.
  • We are thrilled that three of Spains most renowned cancer research organizations have chosen to leverage HTGs innovative technology to improve precision medicine for breast cancer patients, said Byron Lawson, Senior Vice President and Chief Commercial Officer of HTG.
  • The MPD Test is a great example of how the HTG EdgeSeq technology can be used not only for molecular profiling and analysis, but also as a predictive tool for advancing precision medicine.
  • Among the challenges of traditional genomic testing in early-stage HR+/HER2- breast cancer is the wide variation in risk assessment, said Dr. Jos Antonio Lpez-Guerrero, Head of Molecular Biology Laboratory at IVO.

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Retrieved on: 
木曜日, 9月 15, 2022
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DKD, Diabetic nephropathy, IPF, Safety, Muscle, CB1, Metabolic disorder, FDA, Hypertriglyceridemia, NASH, Kidney disease, IND, Obesity, HTG, Diabetes, Pancreas, Patient, Appetite, Liver, Leadership, Doctor of Philosophy, T1D, Metabolic syndrome, Fatty liver disease, Progressive, Pharmacokinetics, T2D, Disease, Conditional sentence, Idiopathic pulmonary fibrosis, Pharmaceutical industry

Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Companys lead program.

Key Points: 
  • Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Companys lead program.
  • Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need.
  • INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including Diabetic Kidney Disease.
  • Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination.

DGAP-News: HomeToGo SE: HomeToGo Shares Admitted to Prime Standard

Retrieved on: 
木曜日, 9月 15, 2022
Frankfurt Stock Exchange, Technology, CFO, Solution, General officer, HTG, Security (finance), Online shopping

HomeToGo shares will, as of September 16, be traded in the Prime Standard of the Frankfurt Stock Exchange, the segment of the regulated market with the highest standard of transparency

Key Points: 
  • HomeToGo shares will, as of September 16, be traded in the Prime Standard of the Frankfurt Stock Exchange, the segment of the regulated market with the highest standard of transparency
    Luxembourg, 15 September 2022 - HomeToGo SE (Frankfurt Stock Exchange: HTG), the marketplace with the worlds largest selection of vacation rentals, has announced that its shares have today been admitted to the Prime Standard of the Frankfurt Stock Exchange, the segment of the regulated market with the highest standard of transparency in Germany and across Europe.
  • Steffen Schneider, CFO, HomeToGo: The uplisting from General to Prime Standard underscores HomeToGos efforts to comply with the capital market best practices and is in line with our impressive growth journey.
  • This promotion will contribute to increased share liquidity, drive long-term shareholder value, and make HomeToGo shares even more attractive and visible to an international audience.
  • While HomeToGo SE's registered office is located in Luxembourg, HomeToGo GmbH is headquartered in Berlin, Germany.

HHS Technology Group, Datavant, and Mathematica Partner to Combat Chronic Kidney Disease

Retrieved on: 
火曜日, 9月 13, 2022
Linda, National Kidney Foundation of Michigan, Software, Adoption, Public, Government, Naval Health Unit, National Kidney Foundation, Chronic kidney disease, Influenza Research Database, COVID-19, Medicare, Machine learning, Risk, Policy, AWS, LLC, Research, Publication, Knowledge, Privacy, Organization, Fortis Healthcare, Kidney disease, CKD, Partnership, Hypertension, HHS, HTG, COVID, Diabetes, Patient, Database, CEO, Population health, Private sector, Solution, Kantō dialect, Technology, Diagnosis, General manager, Method, Death, SAN, Friction, Hospital, Awareness, SVP, Disease, Artificial intelligence, Pharmaceutical industry, Wolfram Mathematica, Medicaid

FORT LAUDERDALE, Fla. and SAN FRANCISCO, Sept. 13, 2022 /PRNewswire/ -- HHS Technology Group, LLC™ (HTG); Datavant, the leader in helping organizations securely connect health data; and Mathematica announced today they are collaborating to offer public and private sector access to invaluable resources to fight the invisible epidemic of chronic kidney disease (CKD) and long-term COVID-19. 

Key Points: 
  • Michigan Medicaid spends over $1 billion yearly on CKD, and available data shows that at least 40% of all COVID-19-related deaths are tied to kidney disease."
  • Individuals with kidney disease are at a significantly higher risk of experiencing poor outcomes from COVID-19, making this research vital.
  • "Chronic kidney disease is preventable through early identification, which makes it all the more agonizing that so many Americans continue to experience this silent killer," said Brett Furst, President of HHS Technology Group.
  • "As a result of this initiative, state Medicaid agencies now have the data analytic tools to move quickly on chronic kidney disease prevention and reduce preventable disease, deaths, and hospitalizations."

DGAP-News: HomeToGo SE: HomeToGo reports strong operational and financial performance in Q2'22, paving the way for break-even profitability by FY'23

Retrieved on: 
火曜日, 8月 16, 2022
Momentum, Q&A, CEO, Preview (subscription service), CFO, Technology, Growth, HTG, Software as a service, Adjustment, Yoy, Frankfurt Stock Exchange, Solution, Interest, CEST, Pharmaceutical industry, Film, Broadcasting, Online shopping, EUR, Service

HomeToGo SE: HomeToGo reports strong operational and financial performance in Q2'22, paving the way for break-even profitability by FY'23

Key Points: 
  • HomeToGo SE: HomeToGo reports strong operational and financial performance in Q2'22, paving the way for break-even profitability by FY'23
    The issuer is solely responsible for the content of this announcement.
  • With a high IFRS Revenues growth of 83.4% vs. Q221, notably 126% vs. Q219, HomeToGo continues to advance its business performance.
  • Dr. Patrick Andrae, Co-founder & CEO of HomeToGo: The second quarter of 2022 marks incredible growth in terms of our strategic priorities and performance.
  • This strong momentum continues into the current Q322, reaching the best month ever for Booking Revenues in July this year.

HTG Molecular Diagnostics Reports Second Quarter 2022 Results

Retrieved on: 
木曜日, 8月 11, 2022
Security, Precision medicine, Drug discovery, GLOBE, CA, AbbVie, HTG, Patent, Sale, Silicon, Conference call, Pfizer, Silicon Valley Bank, Company, Doctor of Philosophy, Drug design, RNA, LSA, HTP, Journal, Frontiers in Medicine, KOL, Publication, University, Nasdaq, Conference, University of California, Irvine, Medical device, Pharmaceutical industry, Video game, Medicine

TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June30, 2022.

Key Points: 
  • TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June30, 2022.
  • Second Quarter 2022 Financial Highlights:
    Revenue for the quarter ended June30, 2022 was $1.5 million, compared with $2.1 million for the same period in 2021, and was comprised entirely of product and product-related services revenue.
  • Net loss from operations for the quarter ended June30, 2022 was $5.7 million, compared with $4.1 million for the same period in 2021.
  • Net loss per share was $(0.54) for the quarter ended June30, 2022 compared with $(0.39) for the second quarter of 2021.

Noridian Partners with HHS Technology Group to Modernize Customer Solutions

Retrieved on: 
火曜日, 8月 9, 2022
Centers for Medicare & Medicaid Services, Industry, Medicare, GLOBE, CEO, HTG, Workload, LLC, Software as a service, Government, FHIR, Patient, MMIS, Medicaid, MESC, CMS, Fast Healthcare Interoperability Resources, Technology, Software, Solution, Accuro Healthcare Solutions, Conference, Risk management, Pharmaceutical industry, Noridian Mutual Insurance Company

FARGO, N.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is excited to announce it will work with software and solutions company HHS Technology Group, LLC (HTG) to modernize solutions for states Medicaid programs.

Key Points: 
  • FARGO, N.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Noridian Healthcare Solutions, LLC (Noridian) , a leader in developing solutions for federal, state and commercial health care programs, is excited to announce it will work with software and solutions company HHS Technology Group, LLC (HTG) to modernize solutions for states Medicaid programs.
  • This collaboration will combine Noridians administrative services with HTGs technology software to develop transformative solutions for provider management and third-party liability services.
  • Working with like-minded technology companies who help us deliver our administrative solutions to customers is essential to enabling access to health care.
  • HHS Technology Group is a software and solutions company serving the needs of commercial enterprises and government agencies.

HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11

Retrieved on: 
木曜日, 8月 4, 2022
Precision medicine, Diagnosis, HTG, Therapy, Drug discovery, RNA, Medical device, Fine chemical

HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.

Key Points: 
  • HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
  • Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTGs proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery.
  • For more information visit www.htgmolecular.com .

CRN® Honoring Jason Magee of ConnectWise in 2022 Top 100 Executives List in the Disruptors Category

Retrieved on: 
火曜日, 8月 2, 2022
Data management, Weapons in Star Trek, GLOBE, United Kingdom, Documentation, Satellite navigation, The Channel Company, Industry, CEO, Ecosystem, Continuum, HTG, National Cybersecurity Center of Excellence, ConnectWise Control, COO, CRN, MSP, Efficiency, Certification, Growth, Member of the Scottish Parliament, Automation, Management

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ConnectWise , the worlds leading software company dedicated to the success of IT solution providers (TSPs), announced today that CRN , a brand of The Channel Company , has recognized Jason Magee, CEO, on its 2022 Top 100 Executives List in the Disruptors category.

Key Points: 
  • TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ConnectWise , the worlds leading software company dedicated to the success of IT solution providers (TSPs), announced today that CRN , a brand of The Channel Company , has recognized Jason Magee, CEO, on its 2022 Top 100 Executives List in the Disruptors category.
  • CRNs Top 100 Executives list shines a light on the executives who are shaking up the status quo, supporting channel partners, and placing big bets on where the market is headed next.
  • CRN commends these visionaries across four sub-categories: the 25 Most Influential Executives, Top 25 Channel Sales Leaders, Top 25 Innovators and Top 25 Disruptors.
  • This marks Magees second consecutive appearance on the CRN Top 100 Executives list.